NCT07114874招募中3 期
A Global, Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety and Tolerability of NBI-1117568 in Adults With Schizophrenia
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 600
- 试验地点
- 60
- 主要终点
- Number of Participants with Treatment-emergent Adverse Events
研究概览
简要总结
This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant has a primary diagnosis of schizophrenia
- •Participants taking prohibited medications, including antipsychotics, must discontinue before study participation
- •Participant must reside in a stable housing situation
排除标准
- •Participant has known hypersensitivity to any component of the formulation of NBI-1117568
- •Participant has an unstable or poorly controlled medical condition or chronic disease
- •Participant is considered by the investigator to be at imminent risk of suicide or injury to self or others
- •Participant has a diagnosis of moderate or severe substance use disorder (with the exception of nicotine or caffeine dependence) within 6 months prior to screening
- •Participant has a positive alcohol test or drug screen for disallowed substances
- •Participant has a history of poor or suspected poor compliance in clinical research studies and/or in the investigator's opinion, the participant is not capable of adhering to the protocol requirements.
- •Note: Other protocol-specified inclusion/exclusion criteria may apply.
研究组 & 干预措施
NBI-1117568
Experimental
Participants will receive NBI-1117568 once daily (QD) orally for up to 36 months.
干预措施: NBI-1117568 (Drug)
结局指标
主要结局
Number of Participants with Treatment-emergent Adverse Events
时间窗: Up to 36 months
次要结局
未报告次要终点
研究者
研究点 (60)
Loading locations...
相似试验
已完成
2 期
Safety and Tolerability Study of Drug to Treat SchizophreniaSchizophreniaNCT00044005Sumitomo Pharma America, Inc.98
已完成
3 期
Long Term Study of RBP 7000 in the Treatment of Subjects With SchizophreniaSchizophreniaNCT02203838Indivior Inc.500
已完成
4 期
Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic SyndromeSchizophreniaNCT01714011University of Malaya175
已完成
3 期
Bifeprunox in the Treatment of SchizophreniaSchizophreniaNCT00193687Solvay Pharmaceuticals986
已完成
3 期
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic EsophagitisEosinophilic EsophagitisNCT04991935Celgene367